{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hirsutism/diagnosis/assessment-for-an-underlying-cause/","result":{"pageContext":{"chapter":{"id":"fc818766-2cdb-52a0-ad0e-7925d2deab29","slug":"assessment-for-an-underlying-cause","fullItemName":"Assessment for an underlying cause","depth":2,"htmlHeader":"<!-- begin field ba90c3cf-ebc6-41f1-8731-7c0266c4967f --><h2>How should I assess for an underlying cause of hirsutism?</h2><!-- end field ba90c3cf-ebc6-41f1-8731-7c0266c4967f -->","summary":"","htmlStringContent":"<!-- begin item b7ff1429-3dc4-48a7-8fb6-e732826f8d25 --><!-- begin field bc452498-89f5-40a3-bed9-4f92f345642f --><ul><li><strong>Ask about, and look for, features of underlying conditions, </strong>such as:<ul><li><strong>Polycystic ovary syndrome (PCOS), </strong>including oligomenorrhoea or amenorrhoea, infertility, acne, central obesity, and acanthosis nigricans.<ul><li>For information on the diagnosis of PCOS, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/polycystic-ovary-syndrome/diagnosis/\">Diagnosis</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/polycystic-ovary-syndrome/\">Polycystic ovary syndrome</a>.</li></ul></li><li><strong>An androgen-secreting tumour, </strong>including sudden onset or rapid progression of hair growth, progression despite treatment, signs of virilization (hair loss from the scalp, voice deepening, increased muscle bulk, clitoromegaly), and a pelvic or abdominal mass.</li><li><strong>Endocrine conditions (uncommonly cause hirsutism),</strong> including: <ul><li>Cushing's syndrome<strong> </strong>—<strong> </strong>facial weight gain (moon face); central obesity; fat deposition on the upper back and between the shoulders; stretch marks; easy bruising; and proximal muscle weakness.</li><li>Non-classical congenital adrenal hyperplasia — family history of adrenal hyperplasia, menstrual dysfunction, infertility. </li><li>Thyroid dysfunction — abnormal thyroid function tests. Hypothyroidism or hyperthyroidism is uncommonly associated with isolated hirsutism.</li><li>Hyperprolactinaemia — galactorrhoea, amenorrhoea, infertility; infrequently presents with hirsutism.</li><li>Acromegaly — increased size of hands or feet and mandible, frontal bossing, deepening of voice; rare cause of isolated hirsutism.</li></ul></li></ul></li><li><strong>Ask about current medication(s)</strong><ul><li>Certain <a class=\"topic-reference internal-reference\" href=\"/topics/hirsutism/background-information/causes/\">drugs</a>, including danazol, sodium valproate, and anabolic steroids, can cause hirsutism.</li></ul></li><li><strong>Ask about family history of hirsutism or hyperandrogenism.</strong></li><li><strong>In all women with an abnormal hirsutism score,</strong><strong> or local sexual hair growth with clinical evidence of a hyperandrogenic endocrine disorder (suggested by sudden-onset or rapidly progressing hirsutism, irregular menses, infertility, galactorrhoea, features of hypothyroidism or Cushing's syndrome, acromegaly, central obesity), </strong>test for elevated androgen levels (serum total testosterone level) using  a reliable specialty assay.<ul><li>If serum total testosterone levels are normal and sexual hair growth is moderate/severe, or sexual hair growth is mild with clinical signs of a hyperandrogenic endocrine disorder (for example menstrual disturbance), measure an early morning serum total and free testosterone by a reliable specialty assay.</li></ul></li><li><strong>In women with local, isolated sexual hair growth, a normal hirsutism score, and no other signs of a hyperandrogenic endocrine disorder,</strong> investigations are not usually necessary unless hair growth progresses despite treatment.</li><li><strong>Consider screening for non-classical congenital adrenal hyperplasia in hyperandrogenemic women, and hirsute women at high risk (even if serum total and free testosterone levels are normal), </strong>for example those with a positive family history, or from a high-risk ethnic group (such as Ashkenazi Jewish, Hispanic, and Eastern European people). <ul><li>Measurement of early morning 17-hydroxyprogesterone levels in the follicular phase is recommended — check with the local laboratory for details on when and how this test should be performed. </li></ul></li></ul><!-- end field bc452498-89f5-40a3-bed9-4f92f345642f --><!-- end item b7ff1429-3dc4-48a7-8fb6-e732826f8d25 -->","topic":{"id":"f7bb546f-c63b-5f36-8592-742d53a300ba","topicId":"6cd0021b-eeb7-4f76-9627-4f095658d33a","topicName":"Hirsutism","slug":"hirsutism","lastRevised":"Last revised in July 2020","chapters":[{"id":"7f1b7b92-6387-5893-b9c1-1b0fe5e6921f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ad41ddff-180c-5c56-9fa8-cfcaa4b301ac","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4e6e27c3-ace8-5785-bc5d-74954333ce03","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84d0d634-74f6-5808-8f94-da5030ec05c6","slug":"changes","fullItemName":"Changes"},{"id":"24cd5147-9eea-5049-abb9-bbff6b2e15e8","slug":"update","fullItemName":"Update"}]},{"id":"bccddc08-eaf5-58bc-b91c-222a0631380a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d59efd74-c7e8-5a58-88a9-274b74de9cc7","slug":"goals","fullItemName":"Goals"},{"id":"3e4b60ae-49dd-58fa-8977-9a8f93804089","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fb5d6918-d9cd-57de-8ef8-09ac15afb519","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fb74a918-ba53-56c2-b640-6a8b38dd4d52","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0a97044d-161a-536d-99bd-e30a0b9553dd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ed166746-cb44-593f-aa91-2daa54e9df51","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"530429b5-0393-529c-874a-7270e7bccb64","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2c5b6cec-8e35-5953-a425-773d40af6f62","slug":"definition","fullItemName":"Definition"},{"id":"7c04b952-69e3-54ba-abf5-964402df757c","slug":"causes","fullItemName":"Causes"},{"id":"1ab4046f-c4e7-520f-893f-e09d2db4390d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"dce06012-6849-5ef4-ab2b-0c84dc64de89","slug":"complications","fullItemName":"Complications"}]},{"id":"0e4a9c3d-b4db-57a6-b036-9e01073ecafc","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a58667b3-2a20-5be2-81aa-4b35ba1bc423","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"fc818766-2cdb-52a0-ad0e-7925d2deab29","slug":"assessment-for-an-underlying-cause","fullItemName":"Assessment for an underlying cause"},{"id":"3e40d667-a42d-56c7-a222-6eb858be7c6d","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"684a1492-2308-5cae-b75d-1460cf238959","fullItemName":"Management","slug":"management","subChapters":[{"id":"eb3e5264-aa93-5618-a326-1f9052e41577","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"61f39625-be0c-52a3-bdb4-7f1b9eaf0ffd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4573c138-4cd9-557f-9ff3-297c6187958a","slug":"topical-eflornithine","fullItemName":"Topical eflornithine"}]},{"id":"1d2fa7d5-926c-5ced-b5ff-0c103d1ddbbc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3154c9fd-0eb5-5ee3-8a69-a18ed1a66193","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"243b8cac-0f37-5266-bf46-8279e00461db","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5fab04c2-7dc7-5ebd-89cd-f693a3cd663f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b5b1cd8e-118a-5aab-bc89-4fa265c0b038","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d0d01f8a-60fc-5ef2-94a6-9d894ebe74d4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"74f5177a-4053-5623-b286-63a07a583386","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"34dca8b6-44ff-5ef5-8816-48aa07f93aff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0e4a9c3d-b4db-57a6-b036-9e01073ecafc","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"ba7f1747-af5b-5413-a422-563cb8467e14","slug":"basis-for-recommendation-d76","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 9b1d3444-cc97-475d-beda-3bc9f32a063a --><h3>Basis for recommendation</h3><!-- end field 9b1d3444-cc97-475d-beda-3bc9f32a063a -->","summary":null,"htmlStringContent":"<!-- begin item d76543a4-4a47-47cc-950d-a87115fca1b5 --><!-- begin field cd7d2773-8d3a-4b52-af5e-3da7a61d4e43 --><h4>Asking about and looking for features of an underlying condition</h4><ul><li>This recommendation is based on Endocrine Society guidelines on <em>Evaluation and treatment of hirsutism in premenopausal women, </em>that advise checking all hirsute women for features suggestive of PCOS, and excluding other treatable conditions such as congenital adrenal hyperplasia, ovarian or adrenal neoplasm, or endocrinopathies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. This is consistent with the approach suggested by experts in review articles on the management of androgen excess and hair disorders in postmenopausal women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Rothman and Wierman, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Blume-Peytavi et al, 2012</a>]. <ul><li>Features of polycystic ovary syndrome (PCOS), androgen-secreting tumours, Cushing's syndrome, and other endocrine conditions are also based on Canadian guidelines on the evaluation and treatment of hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Kini and Ramalingam, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Matheson and Bain, 2019</a>]. </li></ul></li></ul><h4>Asking about current medication(s)</h4><ul><li>This recommendation is based on Canadian clinical practice guidelines on the evaluation and treatment of hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>] and expert opinion that certain drugs, including danazol, sodium valproate, and anabolic steroids, can cause hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Kini and Ramalingam, 2018</a>]. </li></ul><h4>Asking about family history of hirsutism or hyperandrogenism</h4><ul><li>This recommendation is included in the suggested history in Canadian clinical practice guidelines on the evaluation and treatment of hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>]. Family history of hyperandrogenism is common in women with hirsutism and may be consistent with a benign or idiopathic cause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Matheson and Bain, 2019</a>]. </li></ul><h4>Checking total testosterone blood levels in women with an abnormal hirsutism score, or local sexual hair growth with clinical evidence of a hyperandrogenic endocrine disorder</h4><ul><li>This recommendation is based on the Endocrine Society clinical practice guideline <em>Evaluation and Treatment of Hirsutism in Premenopausal Women</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>].<ul><li>The Endocrine Society suggests checking for increased serum total testosterone levels in women with an abnormal hirsutism score because they are more likely to have excess androgen production. It also advises ruling out raised androgen levels in women with any degree of sexual hair growth and clinical evidence of a hyperandrogenic endocrine disorder [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>].</li><li>This recommendation is also supported by expert opinion in a Canadian guideline, <em>Hirsutism: Evaluation and Treatment </em>which advises laboratory investigations (including total testosterone) for women with moderate to severe hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>]. </li></ul></li></ul><h4>No investigations for local, isolated hair growth, a normal hirsutism score, and no other signs of a hyperandrogenic endocrine disorder</h4><ul><li>This recommendation is based on the Endocrine Society clinical practice guideline <em>Evaluation and Treatment of Hirsutism in Premenopausal Women </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. <ul><li>If a woman has unwanted hair growth and regular periods, but does not have an abnormal hirsutism score, the Endocrine Society recommends against testing for increased androgen levels because it is unlikely an underlying medical disorder with an impact on management or outcome will be identified [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>].  </li><li>Canadian guidelines note the questionable benefit of laboratory investigations for mild hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>].  </li></ul></li></ul><h4>Testing for non-classical congenital adrenal hyperplasia</h4><ul><li>This recommendation reflects guidelines from the Endocrine Society that recommend screening selected women for non-classical congenital adrenal hyperplasia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. This is supported by Canadian guidelines that advise assessing serum 17-hydroxyprogesterone in women with hyperandrogenic hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>].</li></ul><!-- end field cd7d2773-8d3a-4b52-af5e-3da7a61d4e43 --><!-- end item d76543a4-4a47-47cc-950d-a87115fca1b5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}